+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Motion Sickness Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896211
  • Report
  • January 2020
  • Region: Global
  • 115 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Baxter International Inc
  • Caleb Pharmaceuticals Inc
  • CVS Health
  • GlaxoSmithKline plc
  • Myungmoon Pharm Co. Ltd
  • Perrigo Company plc
  • MORE
Market Overview

The motion sickness treatment market studied was anticipated to grow with a CAGR of nearly 3.0% during the forecast period. There are certain factors that are driving the market growth, including a rise in the number of travelers across the globe and increased incidences of cardiovascular diseases in the geriatric population which majorly cause motion sickness. For instance, according to United Nations World Tourism Organization (UNWTO), international tourist arrivals increased by 5.4% in 2018 compared to 2017 and this tendency is expected to continue throughout the forecast period which demands higher requirements for motion sickness treatment globally. Also, ongoing research activities in motion sickness drug development and delivery systems are likely to increase the availability of OTC drugs for motion sickness treatment.

Scope of the Report

Motion sickness is a common disorder characterized by a set of symptoms such as dizziness, nausea, and fatigue experienced by a person while traveling due to differences in impulses in the eyes, other body tissues, and sensory receptors. Motion sickness is most commonly observed among children and geriatrics. It is experienced by about 50% to 70% of travelers and even while playing virtual reality (VR) games.

Key Market Trends

Anticholinergic Treatment Segment By Treatment Type is Expected to Hold the Largest Market Share in the Motion Sickness Treatment Market
  • The anticholinergic treatment segment is expected to account for a more significant share of the motion sickness treatment market. The dominance in the revenue share of this segment is due to long-lasting relief, better efficacy, better patient-compliance, and fewer side effects compared to other treatments. Also, the growing demand along with the higher prices of these products is expected to contribute to the highest revenue of the segment during the forecast period.
  • Next to anticholinergics, the antihistamine treatment segment contributes to the second-highest revenue in the global market. This is due to their access to the patients in a wide range of dosage forms like transdermal patches, oral dosage forms such as chewable tablets, lozenges, etc., as per patient requirement. They are also available as prescriptions and various OTC drugs which are expected to account for their significant growth rate in the motion sickness treatment market.
  • By the distribution channel, the retail pharmacies segment is expected to have a high revenue share in the market and is expected to continue during the forecast period. The dominance is owing to the higher preference of self-medication and the access to patients which accounts for the significant share in the market.
North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to account for the largest share of the motion sickness treatment. This is due to increased tourism in the U.S. and preference for highly expensive prescription drugs directly contributes to a significant share of revenue in the region. For instance, according to the UNWTO, in 2018, nearly 52 million International tourists travel from America to Europe resultant in a higher demand for the motion sickness treatment market in the region.

Followed by North America, Europe contributed to the second largest market share owing to a rise in a number of travelers all over the world, increased research activities and investors to develop novel drug delivery systems for motion sickness treatment accounts for the highest revenue.

Globally, the Asia - Pacific region is expected to witness the fastest growth in the forthcoming years due to the presence of global and local players in the Chinese and Indian markets. An increased number of domestic and international travelers are expected to boost the global motion sickness treatment market in the Asia Pacific.

Competitive Landscape

The motion sickness treatment market is moderately competitive and consists of several major players. Few of the major players currently dominating the market are implementing various development strategies such as making mergers and acquisitions, entering into partnerships and thus, expanding their footprint globally. For instance, WellSpring Pharmaceutical Corporation acquired BONINE, an OTC drug for motion sickness, from Prestige Brands Holdings and added to its U.S. OTC nausea franchise, consolidated their market positions in the U.S. While some of the major players are launching simplified and more novel drug delivery systems compared to that of commercial innovator drugs. For example, Caleb Pharmaceuticals introduced the first matrix-type transdermal patch, Ariel TDDS Patch for the treatment of motion sickness. It is much simpler than that of Transderm Scop, the first commercial scopolamine TDDS. Thus, ongoing research activities and developments directly fuel the growth of the global motion sickness treatment market. In terms of market share, the prominent companies that are currently dominating the market are Prestige Consumer Healthcare Inc, WellSpring Pharmaceutical Corporation, Caleb Pharmaceuticals Inc, Myungmoon Pharm Co. LTD, and Reliefband Technologies LLC

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • Baxter International Inc
  • Caleb Pharmaceuticals Inc
  • CVS Health
  • GlaxoSmithKline plc
  • Myungmoon Pharm Co. Ltd
  • Perrigo Company plc
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Number of Travelers and Virtual Reality Exposure Across the Globe
4.2.2 Rise in Adoption of Prescription Motion Sickness Drugs
4.3 Market Restraints
4.3.1 Reluctance in Emerging Countries due to Higher Cost of Prescription Drugs
4.3.2 Excessive Reliance on the OTC and Traditional Medicines
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment Type
5.1.1 Anticholinergics
5.1.2 Antihistamines
5.1.3 Others
5.2 By Distribution Channel
5.2.1 Retail Pharmacies
5.2.2 Online Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 GlaxoSmithKline plc
6.1.2 Perrigo Company plc
6.1.3 Prestige Brands Inc
6.1.4 WellSpring Pharmaceutical Corporation
6.1.5 Caleb Pharmaceuticals Inc
6.1.6 Myungmoon Pharm Co. Ltd
6.1.7 Baxter International Inc
6.1.8 Reliefband Technologies LLC
6.1.9 CVS Health

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • GlaxoSmithKline plc
  • Perrigo Company plc
  • Prestige Brands Inc
  • WellSpring Pharmaceutical Corporation
  • Caleb Pharmaceuticals Inc
  • Myungmoon Pharm Co. Ltd
  • Baxter International Inc
  • Reliefband Technologies LLC
  • CVS Health
Note: Product cover images may vary from those shown